[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351022-105":59,"doc-detail-351022-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","concordance-of-genomic-alterations-in-ovarian-cancer-tissues-and-circulating-tumor-dna-a-pilot-study","Concordance of Genomic Alterations in Ovarian Cancer Tissues and Circulating-Tumor DNA - A Pilot Study","","High-grade serous ovarian carcinoma (HGSOC) shows genomic instability and strong spatial heterogeneity, making single-site tissue sampling incomplete. This pilot study assessed how well circulating tumor DNA (ctDNA) from plasma matches genomic alterations in matched tumor tissue using cell-free DNA (cfDNA) sequencing. Twelve HGSOC patients underwent primary cytoreductive surgery and ctDNA was profiled with a UMI-based cancer panel. Gene-level concordance reached 95.3%, while ctDNA detected a broader mutational spectrum, capturing subclonal variants with high VAF for concordant changes and low VAF for discordant plasma-unique events.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/concordance-of-genomic-alterations-in-ovarian-cancer-tissues-and-circulating-tumor-dna-a-pilot-study/351022/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/concordance-of-genomic-alterations-in-ovarian-cancer-tissues-and-circulating-tumor-dna-a-pilot-study/351022.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the goal of this pilot study?","Question",{"text":112,"@type":113},"To evaluate how concordant genomic alterations are between plasma cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) and matched ovarian tumor tissue in patients with high-grade serous ovarian carcinoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was sensitivity related to mutation detection achieved in this study?",{"text":117,"@type":113},"A UMI-based sequencing approach using the Macrogen Axen Cancer Panel 2 enabled error suppression and a theoretical limit of detection of about 0.36% VAF.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about concordance and mutational breadth?",{"text":121,"@type":113},"Overall gene-level concordance was 95.3%, while liquid biopsy identified a broader mutational spectrum than tissue. Concordant mutations showed higher VAFs, whereas plasma-unique discordant mutations had significantly lower VAFs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351022,1790524928,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nConcordance of Genomic Alterations in Ovarian Cancer Tissues and Circulating-Tumor DNA: A Pilot Study  \nBowon Kang 1,†, Seongmin Kim 2,†, Sanghoon Lee 2 and Jae Yun Song 2, *  \nAcademic Editor: David B. Alexander  \nReceived: 5 December 2025  \nRevised: 17 January 2026  \nAccepted: 26 January 2026  \nPublished: 28 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Medical Science, Korea University Graduate School, Seoul 02841, Republic of Korea  \n2 Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul 02841, Republic of Korea  \n* [Correspondence: yuni105@korea.ac.kr](Correspondence: yuni105@korea.ac.kr)[ ](Correspondence: yuni105@korea.ac.kr)† These authors contributed equally to this work.  \nAbstract  \nHigh-grade serous ovarian carcinoma (HGSOC) is characterized by profound genomic instability and spatial heterogeneity. Liquid biopsy, utilizing circulating tumor DNA (ctDNA), offers a non-invasive approach to capture the comprehensive mutational landscape of the disease. This pilot study evaluated the concordance of genomic alterations between cell-free DNA (cfDNA) and matched tumor tissue in patients with HGSOC. Twelve patients with HGSOC undergoing primary cytoreductive surgery were enrolled. Using the Macrogen® Axen™ Cancer Panel 2 with unique molecular identifier (UMI) technology for error suppression, we achieved a theoretical limit of detection of ~0.36% VAF. The mean cfDNA concentration was 107.3 ng/mL, showing a significant positive correlation with FIGO stage (p = 0.016) . While the sensitivity of cfDNA to detect tissue-confirmed mutations was 57.6%, the overall gene-level concordance was 95.3%, largely driven by negative agreement in wild-type genes. Liquid biopsy revealed a significantly broader mutational spectrum (mean 9.67 alterations/patient) compared to tissue (5.50/patient) . Crucially, concordant mutations exhibited high variant allele frequencies (VAFs) (mean 41.4%), whereas plasma-unique discordant mutations showed significantly lower VAFs (mean 7.31%, p \u003C 0.001) . These preliminary findings suggest that while tissue biopsy likely reflects the dominant clonal population, liquid biopsy may serve as a potential molecular mirror, capturing subclonal variants from spatially distinct metastatic sites and hypoxic niches.  \nKeywords: cell-free DNA; liquid biopsy; ovarian cancer; tumor heterogeneity; UMI sequencing; molecular residual disease  \n1. Introduction  \nOvarian cancer is a genetically complex malignancy characterized by substantial intraand inter-tumoral heterogeneity [1] . This heterogeneity poses a challenge for traditional tissue biopsies, which sample only a portion of a tumor lesion and may miss subclonal mutations present elsewhere. Circulating tumor DNA (ctDNA), the tumor-derived fraction of cell-free DNA (cfDNA) shed into the bloodstream, has emerged as a powerful tool to non-invasively capture a more comprehensive mutational landscape of cancer [2] . Unlike a single-site biopsy, ctDNA reflects DNA contributions from multiple tumor regions and metastatic sites, effectively capturing the spatial heterogeneity of malignant disease [3] . Studies have shown that ctDNA often contains a broader spectrum of mutations than matched tumor tissue, presumably because it aggregates genetic alterations from diverse  \ntumor subclones. For example, comparative analyses have demonstrated that ctDNA can detect additional mutations not found in the primary tumor biopsy due to sampling bias, thereby providing a more complete genomic profile of the cancer [4] . This comprehensive profiling is especially valuable in ovarian carcinoma, where high-grade serous tumors frequently harbor multiple subclonal populations and evolve over time under treatment pressure [5] . In the context of precision oncology,","cbCait1i0ltFZIlp","https://ap.wps.com/l/cbCait1i0ltFZIlp","pdf",1281345,11,"English","# Introduction\n## Liquid biopsy and ctDNA rationale\n## Need to distinguish somatic from germline variants","[{\"question\":\"What was the goal of this pilot study?\",\"answer\":\"To evaluate how concordant genomic alterations are between plasma cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) and matched ovarian tumor tissue in patients with high-grade serous ovarian carcinoma.\"},{\"question\":\"How was sensitivity related to mutation detection achieved in this study?\",\"answer\":\"A UMI-based sequencing approach using the Macrogen Axen Cancer Panel 2 enabled error suppression and a theoretical limit of detection of about 0.36% VAF.\"},{\"question\":\"What did the study find about concordance and mutational breadth?\",\"answer\":\"Overall gene-level concordance was 95.3%, while liquid biopsy identified a broader mutational spectrum than tissue. Concordant mutations showed higher VAFs, whereas plasma-unique discordant mutations had significantly lower VAFs.\"}]","Concordance of Genomic Alterations in Ovarian Cancer Tissues and Circulating-Tumor DNA - A Pilot Study | PDF",1790092307,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53f82620566eef2e2109e8e5e5954273.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/825f3d6dcbfa9ed677dba73f42cb8049.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f81096d76d09a88c178f536c665a4f08.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3e12cdd15e4ef941cbd552d7bab32e6.webp",980,1385]